CompletedNCT00741598
Galantamine or placebo for thinking difficulties in bipolarity
About this title
Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder
Read the official source — NCT00741598Researchers compared Galantamine-ER and placebo, tracking side effects to assess safety in people with bipolarity.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared Galantamine-ER and placebo, tracking side effects to assess safety in people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Boston and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 72
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00741598
- Official title
Show the full official title
The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston · New York
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Galantamine-ER and placebo, tracking side effects to assess safety in people with bipolarity.
Who is behind this study?
The study sponsor is Icahn School of Medicine at Mount Sinai, a university.
Did this study involve medication?
Yes. The study involved medication, including Galantamine-ER and Galantamine placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
